IN SUMMARY: Over the last week, pharma has been blamed for the high cost of healthcare while PBM’s and insurers seem to protected by Teflon. A courageous politician would stand up and admit that our whole healthcare system is to blame, but it’s easier to unite voters against “big pharma.”
KEY TAKEAWAY: Biotech companies that transform themselves into big pharma on the strength of one or two drugs are destined to fail if they forget what made them great. Biogen was a small biotech company who fancied themselves as a player in the big pharma arena. Now, in all likelihood, they are going to be bought.
IN SUMMARY: Nearly three-quarters of Americans over 50 worry about being able to afford prescription drugs for themselves and their families, according to a new AARP nationwide survey. AARP’s campaign will include television ads, a strong social and digital media presence, and grassroots efforts via mail, email, and phone by AARP’s 38 million members, in order to convince lawmakers to act on drug pricing.
IN SUMMARY: The EHR market is still very fragmented as a single “user-friendly” vendor has not been able to lead the way. For pharma marketers, the promise of integrating patient-focused educational material is still the Holy Grail to reach patients at the point of care but will patients feel it crosses a line?
IN SUMMARY: While the media has been doing their best to point the finger at pharma companies for high drug prices patients seem to have other ideas according to research. They understand that the drugs they are taking help them lead better, more productive lives and while the prices on some drugs are high they see it as a warning for could happen if changes aren’t made.
